Circle Pharma Announces Nomination of CID-165, an Oral First-in-class Cyclin D1 RxL Inhibitor, as Development Candidate for its Second Oncology Program December 17, 2025 READ MORE
AACR-NCI-EORTC 2025: First-in-class oral macrocyclic cyclin D1-selective inhibitors demonstrate anti-tumor activity in cyclin D1-dependent tumors October 23, 2025 READ MORE
Circle Pharma Unveils First Preclinical Data from Cyclin D1 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 23, 2025 READ MORE
Circle Pharma Announces Upcoming Poster Presentation Highlighting the Anti-tumor Potential of Cyclin D1 RxL Inhibition at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 14, 2025 READ MORE
AACR Conference on Pediatric Cancer: Investigating the cyclin A/B RxL inhibitor CID-078 in pediatric cancers with RB1 loss and high E2F1 October 1, 2025 READ MORE
Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer September 25, 2025 READ MORE
